Considering the FGFR aberration usually activates AKT-mTOR, PLCγ, and MEK-ERK pathways in cancer 1,2, we used the selective inhibitors or specific siRNAs to block these downstream signalings to test which could downregulate HK2. This evidence concerns the gene AKT1 and cancer.